IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via – , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announces it has selected the corporate communications expertise of , a multifaceted financial news and publishing company for private and public entities.
In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.
NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through in-house manufacturing to commercialization.
As part of the Client Partner relationship, IBN will leverage its investor based distribution network of , , , wire services via , blogs and other outreach tools to generate greater awareness for .
With 15+ years of experience assisting improve communications within the investment community, and a sizable family of , IBN has amassed a collective audience that includes . IBN is uniquely positioned to provide BiondVax Pharmaceuticals the solutions needed to reach a wide audience of investors, journalists and the general public.
“BiondVax is guided by a highly experienced and successful pharmaceutical industry leadership team that includes former senior executives from Novartis, GSK and Bristol-Myers Squibb,” states Chris Johnson, Director of Client Solutions for IBN. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it moves toward a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023. The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected.”
To learn more about BiondVax Pharmaceuticals, please visit the company’s corporate newsroom @
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant Phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, visit the company’s website at
About IBN
consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through (“NNW”) and its , IBN provides: (1) access to a network of wire solutions via to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial ; (3) to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of ; and (6) total news coverage solutions.
For more information, please visit
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
310.299.1717 Office
